Menu
Search
|

Menu

Close
X

Lonza Group AG LONN.S (Virt-X Level 1)

297.70 CHF
-- (--)
As of Mar 18
chart
Previous Close 297.70
Open --
Volume --
3m Avg Volume 354,026
Today’s High --
Today’s Low --
52 Week High 342.00
52 Week Low 218.00
Shares Outstanding (mil) 74.47
Market Capitalization (mil) 22,340.63
Forward P/E 34.24
Dividend (Yield %) 2.75 ( 0.92 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.93 Mean rating from 14 analysts

KEY STATS

Revenue (mm, CHF)
FY18
5,542
FY17
4,548
FY16
4,132
EPS (CHF)
FY18
8.763
FY17
9.489
FY16
5.287
*Note: Units in Millions of Swiss Francs
**Note: Units in Swiss Francs

KEY RATIOS

Price to Earnings (TTM)
vs sector
34.24
40.53
Price to Sales (TTM)
vs sector
4.03
8.82
Price to Book (MRQ)
vs sector
3.57
4.66
Price to Cash Flow (TTM)
vs sector
--
28.75
Total Debt to Equity (MRQ)
vs sector
65.33
17.43
LT Debt to Equity (MRQ)
vs sector
58.23
13.74
Return on Investment (TTM)
vs sector
5.71
12.30
Return on Equity (TTM)
vs sector
10.61
13.41

EXECUTIVE LEADERSHIP

Albert Baehny
Chairman of the Board and Independent Director, Since 2018
Salary: --
Bonus: --
Marc Funk
Chief Executive Officer, Member of the Executive Committee, Since 2019
Salary: --
Bonus: --
Rodolfo Savitzky
Chief Financial Officer, Member of the Executive Committee, Since 2016
Salary: --
Bonus: --
Sven Abend
Chief Operating Officer - Specialty Ingredients, Member of the Management Board, Chief Strategy Officer, Since 2016
Salary: --
Bonus: --
Fridtjof Helemann
Chief Human Resource Officer, Member of the Executive Committee, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Muenchensteinerstrasse 38
BASEL     4052

Phone: +4161.3168111

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

SPONSORED STORIES